GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » 5-Year ROIIC %

GenMark Diagnostics (GenMark Diagnostics) 5-Year ROIIC % : 0.00% (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. GenMark Diagnostics's 5-Year ROIIC % for the quarter that ended in Dec. 2020 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for GenMark Diagnostics's 5-Year ROIIC % or its related term are showing as below:

GNMK's 5-Year ROIIC % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.44
* Ranked among companies with meaningful 5-Year ROIIC % only.

GenMark Diagnostics 5-Year ROIIC % Historical Data

The historical data trend for GenMark Diagnostics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics 5-Year ROIIC % Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GenMark Diagnostics's 5-Year ROIIC %

For the Medical Devices subindustry, GenMark Diagnostics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's 5-Year ROIIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's 5-Year ROIIC % falls into.



GenMark Diagnostics 5-Year ROIIC % Calculation

GenMark Diagnostics's 5-Year ROIIC % for the quarter that ended in Dec. 2020 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -11.0996244 (Dec. 2020) - -41.5723815 (Dec. 2015) )/( 67.803 (Dec. 2020) - 18.583 (Dec. 2015) )
=30.4727571/49.22
=61.91%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


GenMark Diagnostics  (NAS:GNMK) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


GenMark Diagnostics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008